Thesis (Ph. D.) -- University of Texas Southwestern Medical Center at Dallas, 2005. / Vita. Bibliography: 155-170.

Colorectal cancer (CRC) is the third leading cause of cancer-related death in women and fourth in men globally. While expansions in preventative measures have increased the detection of CRC at the early stages of disease, only 40% of CRC patients are diagnosed when the disease is at a local stage. Moreover, many anti-cancer drugs fail to significantly improve the life expectancy of patients due to innate and acquired resistance, underscoring a need for better diagnostic and therapeutic strategies for CRC. Immunoglobulin-containing and proline-rich receptor-1 (IGPR-1) is a novel cell adhesion molecule (CAM) that was recently identified in our laboratory. IGPR-1 is expressed in epithelial and endothelial cells and promotes cell-cell adhesion. Expression of IGPR-1 in endothelial cells regulates angiogenesis; however, its role in epithelial cells, particularly cancer cells with an epithelial origin, remains unknown. The overall goal of this study was to investigate the possible function of IGPR-1 in CRC tumor cell growth and response to chemotherapeutic agents. Specifically, we aimed to test the hypothesis that increased expression of IGPR-1 in CRC tumor cells promotes cell survival and contributes to the resistance of tumor cells to doxorubicin. Human CRC tumor cell lines, HCT116 and HT29, were transduced via a retroviral system to express IGPR-1 or empty retroviral vector pQCXIP. The effect of overexpression of IGPR-1 in HCT116 and HT29 cells was measured by MTT assay in non-adherent 24-well plates. In addition, cells were viewed under a light microscope, and images were taken to assess multicellular aggregation. Results demonstrated that expression of IGPR-1 in HCT116 and HT29 tumor cells promoted CRC tumor cell growth, increased multicellular aggregation, and stimulated resistance to the conventional chemotherapeutic agent doxorubicin in non-adherent cell culture conditions in vitro. Intriguingly, treatment of cells with doxorubicin promoted phosphorylation of IGPR-1 at serine 220 (Ser220), suggesting a critical role for phosphorylation of IGPR-1 in the development of resistance to chemotherapeutics. In addition, non-adherent cell culture conditions promoted activation of the key pro-apoptotic kinase, p38 MAPK in CRC tumor cells. Ectopic expression of IGPR-1 reversed this activation. This data suggests that IGPR-1, by suppressing p38 activity, in part, promotes tumor cell survival and increases the resistance of tumor cells to the killing effects of doxorubicin. Our findings are the first to demonstrate that IGPR-1 promotes CRC tumor cell growth and increases the resistance of CRC tumor cells to the cytotoxic effects of chemotherapeutic agents. The data suggests that IGPR-1 plays an important role in CRC by inhibiting the cellular apoptotic response and promoting chemotherapeutic resistance. Finally, IGPR-1 phosphorylation at Ser220 in response to doxorubicin may account for the IGPR-1-mediated development of resistance to doxorubicin in CRC.

Abstract Respiratory syncytial virus (RSV) infection may be associated with the development of asthma and atopy. The aim of the present study was to investigate this association and the related immunological mechanisms. Seventy-six children admitted to Oulu University Hospital in 1991–1994 for an RSV infection at an age of less than 12 months and healthy controls were called for a visit at the age of 6–10 years. Twenty subjects (26%) had asthma compared with 12 controls (16%) (difference 11%, 95% confidence interval (CI) –3% to 24%). Asthma had been diagnosed significantly earlier in the subjects. Eight per cent of the subjects had at least one positive skin prick test as compared with 43% of the controls (difference –35%, 95% CI –50% to –19%). Serum concentrations of interferon-γ and soluble intercellular adhesion molecule -1 were significantly higher among the subjects than among the controls and among the subjects with asthma or current wheezing than among the corresponding controls. All children born in Finland in 1986–1995 were arranged in birth cohorts by month and year of birth and grouped by exposure to an RSV epidemic at age 0–6 months, resulting in 97 exposed and 23 unexposed cohorts. The proportions of children taking asthma medication or receiving special reimbursement for asthma medication in 1995–2002 were similar in the unexposed and exposed cohorts. Altogether 47 children born between August and November 2001 with a cord blood sample taken were admitted to hospital (n = 26) or seen in an outpatient department (n = 21) for RSV infection before the age of six months. Twenty-eight children had some other respiratory viral infection and 84 children formed a group of healthy controls. High scores on a factor combining the cord blood interleukin-6 and interleukin-8 responses (as derived by factor analysis) were shown in logistic regression analysis to predict hospitalization for RSV infection by comparison with the healthy controls (odds ratio 2.29, 95% CI 1.21 to 4.33). We suggest that RSV does not induce asthma but inborn features of immunity affect the severity of RSV infection and the postinfectious development of asthma.

The immunoglobulin superfamily (IgSF) is a large protein superfamily of membrane and soluble proteins that influence recognition, binding, and adhesion. Among members of this family are cell adhesion molecules (CAMs), which form cell-cell contact points that play key roles in development, cell polarization, and cellular fate. Cadherins (CADs) are calcium-dependent proteins of the adherens junction (AJ), and polarize epithelium and endothelium. The tight junction (TJ) is a multiprotein junctional complex whose function is to control the permeability of the paracellular pathway. At the membrane level, TJs are composed of three types of proteins: claudins (CLDNs), occludin (OCLN) and junctional adhesion molecules (JAMs). JAMs are members of the IgSF while CLDN and OCLN are 4-α-helix membrane proteins. Although JAMs are part of the TJ and reside in the same ultrastructure, they are similar to CADs in their secondary, tertiary, and quaternary protein structure. Crystallographic studies of CADs in the presence of calcium yielded trans interactions that resulted in cell-cell contacts. In the absence of calcium, CADs form cis interactions that do not form cell-cell interactions. The crystal structure of JAM-A, has a quaternary organization of a cis dimer. In spite of the many similarities, a link between CADs and JAMs remains unclear. Beyond this point, the association between JAMs, CLDNs, and OCLN in the TJ is vaguely understood. The JAM family (JAM-A, -B, -C and 4) and their tissue-specific distribution indicate that they are key to understanding the TJ’s function and the interplay with the AJ. JAM-A has been used as a prototype for the other three members of the family, but based on current evidence we hypothesized that these proteins may display unique properties to support TJ’s function in a given tissue. Are JAMs affected by calcium just as CADs? Do CLDNs and OCLN make direct contact with JAMs? Do JAMs coordinate the interplay between TJ and AJ? We designed a strategy based on recombinant proteins and biophysical methods to answer these questions. First, we fused the extracellular domain of each JAM to maltose-binding protein (MBP). Our results indicate that JAM proteins have similar secondary structures, but unique tertiary structures. Surface Plasmon Resonance experiments showed that JAM proteins favored heterotypic compared to homotypic interactions. Second, we addressed the effects of cations (Ca2+, Mg2+, Cu2+, Fe2+, Fe3+, and Zn2+) on JAM-A. The exposure of JAM-A to the resulted in changes in its secondary, tertiary structure, and homotypic binding affinity. Finally, we addressed whether cations had an effect on the other TJ components and if there is an interplay with E-CAD. We determined that in the assembly of a simple TJ and AJ, JAM-A and E-CAD are calcium-dependent, while CLDN1 and OCLN are calcium independent. We conclude that TJ components such as CLDN1 and OCLN may work as anchors to maintain cell-cell interactions while JAM-A and E-CAD would be regulated by cations in order to accommodate other homeostatic functions.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20084号 / 医博第4177号 / 新制||医||1018(附属図書館) / 33200 / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 山田 亮, 教授 椛島 健治 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

Polysialylated NCAM (polySia-NCAM) is re-expressed in a number of tumours, including small cell lung carcinoma and neuroblastoma and is strongly associated with aggressive, invasive and metastatic tumours in the clinic. SiRNA knockdown of the polysialyltransferases (polySTs), the enzymes responsible for polysialylation of neural cell adhesion molecule (NCAM), has been shown to abolish cell migration. PolySia-NCAM is thus a highly attractive novel therapeutic target. A library of potential polyST inhibitors has been synthesised, using substrate-based design and computational chemistry. Compounds synthesised include N-acylmannosamine analogues, thio-linked CMP-sialic acid analogues, N-acyl modified sialic acids and compounds incorporating elements of both approaches. Novel methodology development in the synthesis of many of the compounds is described, notably a novel route to N-acyl sialosides. In addition, compounds identified from in silico screening were considered. Routes to synthesis and isolation of analogues of biologically active compounds are described. Using an enzyme assay, compounds were evaluated for their ability to reduce polySia synthesis through polyST inhibition. Effects of agents on polySia expression in cells, and the ability of compounds to reduce cell migration in vitro was studied using a wound healing ‘scratch assay’. The data from these experiments revealed a number of potent modulators of polySia assembly and their efficacy in reducing cell migration, as well as the limits of the biosynthetic pathway to accept unnatural sialic acid precursors. This is the first example of polyST inhibition modulating tumour cell migration, and points to the potential of the polysialyltransferases as a therapeutic target in metastatic tumours. / EPSRC and BACR / The full text will be available at the end of the extended embargo: 5th March 2027

Neuroblastoma is a highly metastatic and invasive tumour with poor prognosis. Despite recent advances in the treatment of neuroblastoma, mortality is still high due to uncontrolled metastatic disease, and novel therapeutic approaches for the treatment of neuroblastoma are therefore desperately needed. A potential novel approach for therapy of neuroblastoma relates to the polysialic acid decoration of the neural cell adhesion molecule (PSANCAM). PSA-NCAM is selectively re-expressed in a number of tumours including neuroblastoma, where it is thought to modulate tumour dissemination. Expression is strongly associated with poor clinical prognosis and an aggressive tumour phenotype. Inhibition of the enzymes responsible for synthesis of PSA, the polysialyltransferases (polySTs) presents a novel and selective therapeutic opportunity. The aims of the studies described in this thesis are to evaluate PSANCAM expression and function in neuroblastoma, and to develop and utilise cell-based models to pharmacologically investigate novel polyST inhibitors. PSA-NCAM was seen to be highly expressed in neuroblastoma clinical specimens and associated with phenotypes of tumour aggressiveness. A screening panel consisting of cell lines with a range of PSA-NCAM expression types was established and utilised to develop assays for pharmacologically assessing novel polyST inhibitors. Using cytidine monophosphate (CMP), a naturally-occurring inhibitor of polySTs, the robustness of the assays was confirmed before progression to evaluate novel molecules. From 16 compounds identified in an in vitro screen of polyST inhibition, three promising polyST inhibitors were identified. These promising polyST inhibitors modulated PSA-NCAM expression on the tumour cell surface and led to a significant reduction in cell migration. Therefore the work presented in this thesis suggests that targeting polySTs is a promising novel therapeutic strategy for neuroblastoma and further research in this area is warranted. / Mu'tah University and Jordan Armed Forces, Hashemite Kingdom of Jordan. / The full text will be available at the end of the extended embargo period: 5th March 2027

La sclérose en plaques (SP) est une maladie neuro-inflammatoire caractérisée par l’invasion de cellules immunitaires périphériques dans le système nerveux central (SNC), entraînant une perte de myéline à des endroits bien délimités appelés « plaques » ou lésions. Les processus neuroinflammatoires sont associés au dommage des neurones et oligodendrocytes (OLs) en SP. Les mécanismes sous-tendant cette dégradation des OLs par les cellules immunitaires en SP sont toutefois encore mal compris. Les lymphocytes T CD4 activés, notamment les sous-types proinflammatoires Th1 et Th17, jouent un rôle clé dans la pathobiologie de la SP et de son modèle murin l’encéphalite auto-immune expérimentale (EAE). Nous avons donc choisi d’investiguer leur contribution à l’endommagement des OLs en neuroinflammation. Pour ce faire, nous avons premièrement caractérisé les interactions entre les lymphocytes Th17 et les OLs matures in vivo à l’aide de l’imagerie intravitale chez la souris EAE (microscopie deux photons) et in vitro en utilisant des cultures primaires humaines. Ceci nous a permis de mettre en évidence que les lymphocytes pro-inflammatoires Th17 adhèrent de façon prolongée aux OLs et leur causent plus de dommage que les lymphocytes anti-inflammatoires Th2. Après avoir établi que le contact avec les lymphocytes Th17 entraîne tout d’abord la perte des prolongements cellulaires puis la mort des OLs, nous avons identifié deux mécanismes à l’origine de ces dommages. En effet, tandis que la sécrétion de glutamate par les lymphocytes Th17 à proximité des OLs entraîne une perte des prolongements cellulaires de ces derniers et une diminution de leur capacité à myéliniser, la sécrétion de granzyme B mène à la mort des OLs. Dans le but de comprendre comment prévenir les dommages causés par les lymphocytes Th17 aux OLs en SP, nous avons par la suite étudié les mécanismes sous-tendant le contact entre les deux types cellulaires. Comme nous avons confirmé que les OLs matures n’expriment pas le MHC II au niveau protéique, nous avons caractérisé l’expression par les OLs de molécules d’adhérence cellulaire (CAMs) qui seraient susceptibles de sous-tendre l’adhérence des lymphocytes Th17. Nous avons découvert que cette interaction est notamment médiée par ALCAM, et que bloquer cette molécule permet de diminuer le dommage aux OLs médié par les Th17 in vitro. A l’inverse, l’expression et/ou la sécrétion d’ICAM-1 par les OLs semble avoir un effet protecteur face aux lymphocytes Th17. En résumé, nous avons distingué de nouveaux mécanismes impliqués dans le dommage aux OLs en neuroinflammation et identifié de nouvelles cibles thérapeutiques prometteuses pour la protection des OLs en SP. / Multiple Sclerosis (MS) is a neuroinflammatory disease characterized by infiltration of immune cells into the central nervous system (CNS), demyelination in multifocal areas called “plaques” or lesions, and damage to neurons and oligodendrocytes (OLs). The mechanisms underlying immune-mediated injury to OLs in MS remains only partially understood. Activated CD4 T cells, in particular pro-inflammatory subsets Th1 and Th17, play an important role in the pathobiology of MS and its animal model experimental autoimmune encephalitis (EAE). We set out to investigate their contribution to immune-mediated oligodendrocytic damage in neuroinflammation. We first characterized the interactions between Th17 cells and mature OLs in vivo using live imaging of EAE mice (two photon microscopy) and in vitro using human primary cell cultures. We found that pro-inflammatory Th17 cells form prolonged contacts with OLs and cause greater harm compared to anti-inflammatory Th2 cells. After demonstrating that contact with Th17 cells leads first to destruction of cell processes and then death of OLs, we identified two mechanisms underlying these deleterious impacts. Indeed, while secretion of glutamate by Th17 cells in contact with OLs is associated with damage to OLs cell processes and impairment of their myelinating capacity, secretion of granzyme B leads to OLs death. To better understand how to prevent Th17-mediated OLs injury in MS, we next studied mechanisms involved in the interaction between these two cell types. As we confirmed that mature OLs do not express MHC II at the protein level, we characterized expression of cell adhesion molecules (CAMs) by OLs that could mediate Th17 cell adhesion. We discovered that ALCAM contributes to OLs and Th17 cells interactions, and that blocking this olecule reduces Th17-mediated OL damage in vitro. Inversely, ICAM-1 expression and/or secretion by OLs seems to have a protective effect in neuroinflammatory conditions. In summary, we have uncovered new mechanisms implicated in OLs njury in neuroinflammation and have identified potential novel therapeutic targets for neuroprotection in MS.

No description available.